Molecular markers of the progression of conjunctival neoplastic epithelial lesions and its correlation with P16 and HPV expression

---

Original Article

Author Details : N Nikolaishvili, George Chichua, George Burkadze, Shota Kepuladze*

Volume : 10, Issue : 1, Year : 2023

Article Page : 40-43

https://doi.org/10.18231/j.ijpo.2023.007

Suggest article by email

Get Permission

---

Abstract

Epithelial lesions of the conjunctiva include both benign and transitional malignant and malignant lesions., Therefore, it is important to identify molecular markers of malignant progression of these lesions. The aim of our study was to study molecular markers determining the risk of progression of epithelial neoplastic processes of the conjunctiva. The following markers were detected by standard immunohistochemical methods: Ki67, PHH3, Bcl2, P16, HPV16/18, P53, P63 and CK7.A squamous-epithelial index was also derived by evaluating standard hematoxylin-eosin (H&E)-stained fluorescence and the P63/CK7 ratio. The results of the study showed that during the progression of intraepithelial neoplasia of the conjunctiva, the content of squamous epithelium and, accordingly, the squamous-gland index increases significantly. In addition, according to proliferative and apoptotic characteristics, conjunctival intraepithelial lesions can be divided into two groups, namely, low-grade intraepithelial neoplasia and high-grade intraepithelial neoplasia.

Keywords: Conjunctival Neoplasms, Conjunctival Dysplasia, Conjunctival intraepithelial neoplasm, Conjunctival squamous cell carcinoma

How to cite : Nikolaishvili N, Chichua G, Burkadze G, Kepuladze S, Molecular markers of the progression of conjunctival neoplastic epithelial lesions and its correlation with P16 and HPV expression. Indian J Pathol Oncol 2023;10(1):40-43

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.